Novartis AG ADR (NVS)vsPfizer Inc (PFE)
NVS
Novartis AG ADR
$148.38
-2.51%
HEALTHCARE · Cap: $289.19B
PFE
Pfizer Inc
$26.04
-2.70%
HEALTHCARE · Cap: $148.19B
Smart Verdict
WallStSmart Research — data-driven comparison
Pfizer Inc generates 12% more annual revenue ($63.32B vs $56.58B). NVS leads profitability with a 23.9% profit margin vs 11.8%. NVS appears more attractively valued with a PEG of 4.11. PFE earns a higher WallStSmart Score of 55/100 (C).
NVS
Hold49
out of 100
Grade: D+
PFE
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-65.2%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
+13.8%
Fair Value
$30.21
Current Price
$26.04
$4.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Strong operational efficiency at 31.6%
Large-cap with strong market position
Reasonable price relative to book value
Generating 2.2B in free cash flow
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Distress zone — elevated risk
Expensive relative to growth rate
Earnings declined 10.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : PFE
The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : PFE
The primary concerns for PFE are Altman Z-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
NVS profiles as a declining stock while PFE is a value play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
PFE is growing revenue faster at 5.4% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
PFE scores higher overall (55/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Pfizer Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?